News stories about Kura Oncology (NASDAQ:KURA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kura Oncology earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.1122286389366 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of equities analysts have recently issued reports on KURA shares. Wedbush started coverage on shares of Kura Oncology in a report on Tuesday, December 26th. They issued a “buy” rating and a $19.00 price target for the company. BidaskClub upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, January 24th. Cann reiterated a “buy” rating and issued a $30.00 price target on shares of Kura Oncology in a report on Friday, February 16th. Citigroup set a $28.00 price target on shares of Kura Oncology and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a report on Wednesday, March 21st. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $22.00.
Shares of KURA traded down $0.40 during trading hours on Friday, reaching $16.40. The company had a trading volume of 114,648 shares, compared to its average volume of 227,129. The company has a quick ratio of 9.44, a current ratio of 9.44 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $547.01, a PE ratio of -10.79 and a beta of 4.21. Kura Oncology has a 12-month low of $5.90 and a 12-month high of $24.02.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Monday, March 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.01). research analysts anticipate that Kura Oncology will post -1.43 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.thelincolnianonline.com/2018/04/22/kura-oncology-kura-given-daily-news-sentiment-score-of-0-08.html.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.